Kazia Therapeutics Ltd - Company Profile
Powered by 
All the sales intelligence you need on Kazia Therapeutics Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Kazia Therapeutics Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Kazia Therapeutics Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Kazia Therapeutics Ltd (Kazia) is an oncology-focused biotechnology company developing innovative therapies for a range of cancers. The company’s pipeline is led by two drug candidates: paxalisib (previously known as GDC-0084) and EVT801, both of which are in active development.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company is actively engaged in R&D initiatives focusing on the development of new therapies for brain cancer, particularly glioblastoma, through its lead drug candidate, Paxalisib. It is collaborating with QIMR Berghofer Medical Research Institute to explore novel uses of Paxalisib in solid tumors, leveraging its potential as an immune modulator. Additionally, Kazia is developing EVT801, a first-in-class drug candidate targeting VEGFR3, which aims to inhibit the formation of new blood and lymphatic vessels around tumors, potentially reducing metastasis and enhancing the efficacy of immuno-oncology drugs. In FY2025 company invested AUD6.3 million in research and development during the specified period, compared to AUD15.5 million in 2024.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer